	US 12,338,283 B2
	Methods for targeting the immune checkpoint PD1 pathway for treating pulmonary fibrosis
Paul W. Noble, Beverly Hills, CA (US); Dianhua Jiang, Encion, CA (US); and Carol Jiurong Liang, Encino, CA (US)
Assigned to Cedars-Sinai Medical Center, Los Angeles, CA (US)
Filed by CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US)
Filed on Jun. 13, 2023, as Appl. No. 18/333,869.
Application 18/333,869 is a continuation of application No. 16/652,966, granted, now 11,725,056, previously published as PCT/US2018/054244, filed on Oct. 3, 2018.
Claims priority of provisional application 62/567,513, filed on Oct. 3, 2017.
Prior Publication US 2023/0391874 A1, Dec. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/2818 (2013.01) [A61P 35/00 (2018.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01)]

15 Claims

1. A method for reducing progression of progressive pulmonary fibrosis in a subject, the method comprising:

administering to the subject having idiopathic pulmonary fibrosis (IPF) a pharmaceutical composition comprising a therapeutic amount of a therapeutic agent targeting CD274 expressing cells in IPF lung fibroblasts,

wherein the subject has a higher level of total protein expression of PD-L1/CD274 in lung tissue, as compared to a control subject not suffering from pulmonary fibrosis, and

wherein the therapeutic agent comprises an inhibitor of programmed death receptor-ligand 1 (PD-L1) selected from the group consisting of atezolizumab, avelumab, durvalumab, MDX-1105, YW243.55.S70, and CA-170.